A Critical Role for Transforming Growth Factor-β but Not Interleukin 4 in the Suppression of T Helper Type 1-mediated Colitis by CD45RB^low CD4^+ T Cells

By Fiona Powrie,* Joseph Carlino,† Michael W. Leach,§ Smita Mauze,* and Robert L. Coffman*

Summary

A T helper type 1 (Th1)-mediated colitis with similarities to inflammatory bowel disease in humans developed in severe combined immunodeficiency mice reconstituted with CD45RB^high CD4^+ splenic T cells and could be prevented by cotransfer of CD45RB^low CD4^+ T cells. Inhibition of this Th1 response by the CD45RB^low T cell population could be reversed in vivo by an anti–transforming growth factor (TGF) β antibody. Interleukin (IL) 4 was not required for either the differentiation or function of protective cells as CD45RB^low CD4^+ cells from IL-4-deficient mice were fully effective. These results identify a subpopulation of peripheral CD4^+ cells and TGF-β as critical components of the natural immune regulatory mechanism, which prevents the development of pathogenic Th1 responses in the gut, and suggests that this immunoregulatory population is distinct from Th2 cells.

Mucosal immune responses are highly regulated to allow activation of effector mechanisms that eliminate pathogenic microorganisms while specifically preventing cell-mediated inflammatory responses against dietary antigens and enteric flora. It has been suggested that a breakdown in this mucosal immune regulation is important in the development of idiopathic inflammatory bowel disease (IBD) in humans (1). Dissection of the regulatory pathways that act normally to prevent the development of pathogenic immune responses in the intestine may therefore be key to the understanding of the pathogenesis of human IBD.

We and others have described a model of colitis in mice that has proven useful for dissecting the mechanisms of this form of immune regulation. Colitis was induced in immunodeficient C.B-17 scid mice by transfer of the CD45RB^high subset of CD4^+ T cells from normal C.B-17 (2) or congenic BALB/c (3, 4) donors. Progressive colon inflammation was caused by a dysregulated Th1 response as CD4^+ T cells purified from the lamina propria of diseased mice produced very high levels of IFN-γ, and TNF and disease was prevented by systemic treatment with antibodies to IFN-γ or TNF or with recombinant IL-10 (4). Significantly, transfer of the reciprocal CD45RB^low population did not result in disease, and this population, when transferred together with CD45RB^highCD4^+ T cells, completely inhibited disease development (3–5). These data identify a subpopulation of CD4^+ T cells, present in normal mice, that are critical for the regulation of pathogenic Th1 responses in the gut.

It seems likely that the inhibition of colitis transferred by CD45RB^low cells is mediated via the production of immunosuppressive cytokines. Th2 cells are known to inhibit Th1 effector cell development and function, principally by the production of IL-4 and IL-10 (6–8). More recently, TGF-β has been shown to be a mediator of the induced suppression associated with oral tolerance to foreign antigens (9, 10). Such TGF-β–producing regulatory cells are often found together with Th2-like cells; however, it is not known whether these cells constitute part of the Th2 subset or represent a distinct subset of cells. Here, we use neutralizing anti–TGF-β mAbs and IL-4-deficient mice to examine the role of these cytokines in the suppression of Th1-mediated colitis by CD45RB^lowCD4^+ T cells and to examine the relationship of regulatory cells to Th2 cells.

Materials and Methods

Mice. Specific pathogen–free BALB/c and C.B-17 scid mice were obtained from Simonsen Laboratories (Gilroy, CA); 129/SvEv mice were obtained from Taconic Farms, Inc. (Germantown, NY). Mice were maintained in the Animal Care Facility of the DNAX Research Institute. 129SvEv RAG-2–deficient mice and 129/SvEv IL-4T (IL-4-deficient) mice were bred and maintained in the Animal Care Facility of the DNAX Research Institute. C.B-17 scid mice and RAG-2–deficient mice were housed in microisolator cages with sterile filtered air. Female mice were used at 8–12 wk of age.

Antibodies. The following mAbs were used for cell purification: AMS-32.1, anti-I-A^d (PharMingen, San Diego, CA); 2-43,
were purified from the spleens of mice as previously described. The resulting antibodies were >98% pure and contained <3 EU endotoxin per milligram of protein.

Cell Purification and Flow Cytometry. CD4^+ T cell subsets were purified from the spleens of mice as previously described (3). Briefly, cells were depleted of B220^+, MAC-1^-, I-A^d, and CD8^+ cells by negative selection using sheep anti-rat-coated Dynabeads (Robbins Scientific Corp., Sunnyvale, CA). The remaining cells were labeled with FITC-conjugated anti-CD45RB (25 μg/ml) and PE-conjugated anti-CD4 and fractionated into CD4^+CD45RB^high and CD4^+CD45RB^low fractions by two-color sorting on a FACSTAR PLUS (Becton Dickinson & Co.). All populations were >98% pure on reanalysis.

Reconstitution of C.B-17 scid Mice with T Cell Subpopulations. C.B-17 scid mice were injected intraperitoneally with 100 μl of PBS containing sorted CD4^+ T cell subpopulations or unseparated CD4^+ T cells. Anticytokine or control mAbs were injected intraperitoneally in PBS.

Microscopic Examination of Colon. Colonos were removed from mice 8–18 wk after T cell reconstitution and fixed in PBS containing 10% formaldehyde. 6-μm paraffin-embedded sections were cut and stained with hematoxilin and eosin. Microscopic sections were graded semiquantitatively as 0 (no change) to 5 (most severe) in a blinded fashion by the same pathologist (M.W. Leach).

Nucleic Acid Preparation and Semiquantitative PCR of Cytokine mRNA. Quantitation of cytokine mRNA in the colon was performed as previously described (3). Briefly, RNA was prepared from 40–200-mg pieces of distal colon by a modification of the guanidium isothiocyanate method. 2–3 μg of RNA from test samples was reverse transcribed using Superscriptase II RNAse H-reverse transcriptase (GIBCO BRL, Gaithersburg, MD). IFN-γ, TNF-α, and hypoxanthine phosphoribosyl transferase (HPRT) cDNAs were amplified by PCR and detected by dot blot hybridization and phosphoimaging. Relative quantitation of samples was performed using quantitation of the housekeeping enzyme HPRT as an internal standard. HPRT levels in the samples were measured first, and samples with equivalent amounts of HPRT were then analyzed for cytokine cDNA. For each cytokine, the standard Th cDNA was run and specific cytokine levels were determined (IFN-γ 156 ± 1.2 pg, TNF-α 10 ± 0.019 ng). Units of specific cytokine were determined for each sample by comparison with a standard curve constructed with cDNA from pooled RNA of an activated Th1 and Th2 clone. 1 U of cytokine was defined as the amount in 1 ng Th standard cDNA, and values were expressed as units of cytokine/10^5 U HPRT.

Results

Suppression of Colitis by CD45RB^high CD4^+ T Cells Is Dependent on TGF-β. In previous studies, mice restored with CD45RB^high and CD45RB^lowCD4^+ T cells remained protected from colitis when treated with anti-IL-4, anti-IL-10, or both mAbs (5), suggesting that suppression of colitis was mediated by other immunosuppressive cytokines. To test the role of TGF-β, mice reconstituted with CD45RB^high and CD45RB^lowCD4^+ cells were treated with a mouse mAb that neutralized TGF-β1, 2, and 3 (12). In the initial experiments (Table 1, protocol 1), mice were treated with 2 mg anti-TGF-β at the time of reconstitution followed by 1 mg weekly for 6 wk and then killed for histological examination at 7 wk after transfer. Neutralization of TGF-β partially, but significantly, diminished the ability of CD45RB^low CD4^+ T cells to protect from colitis. The average colitis score in these mice was 2, and 6 of 11 mice developed severe colitis compared with an average colitis score of 0.3 and zero incidence of severe colitis in isotype control–treated mice (Table 1, protocol 1). Anti-TGF-β–treated mice that developed severe colitis also developed a wasting disease, indistinguishable from mice restored with CD45RB^highCD4^+ T cells alone (Table 1). Anti-TGF-β treatment of unreconstituted scid mice (Table 1) or scid mice reconstituted only with CD45RB^lowCD4^+ T cells alone (data not shown) did not induce colitis or wasting, demonstrating that the antibody did not cause disease in the absence of the CD45RB^high population.

To address the possibility that insufficient antibody was being administered to inhibit TGF-β activity completely, the weekly dose of anti-TGF-β was doubled to 2 mg/wk in subsequent experiments (Table 1, protocol 2). At this dose, 100% (7/7) of mice given a mixture of CD45RB^high and CD45RB^lowCD4^+ T cells developed severe colitis and wasting disease, a frequency indistinguishable from mice given CD45RB^highCD4^+ T cells alone (data not shown). These mice did not cause disease in the absence of the CD45RB^low population.

Colitis Induced in Recipients of CD45RB^high and CD45RB^low CD4^+ T Cells Treated with Anti-TGF-β Is Identiﬁcal to Colitis Induced by CD45RB^high Cells Alone. Colitis induced by the CD45RB^highCD4^+ population has been shown to be a Th1 response mediated by IFN-γ and TNF (4). To determine whether the disease that developed in anti-TGF-β–treated mice restored with both CD45RB^high and CD45RB^low cells had a similar pathogenesis, colons were isolated from these mice 7 wk after T cell reconstitution and tested by reverse transcriptase–PCR analysis for the expression of IFN-γ and TNF-α mRNA (Fig. 2). Mice restored with CD45RB^high cells and mice restored with CD45RB^high and CD45RB^low cells and treated with anti-TGF-β had 7–8- and 6–10-fold higher levels, respectively, of TNF-α and IFN-γ mRNA than mice protected from colitis by cotransfer of both T cell subsets. The extensive similarities in kinetics, histology, and cytokine mRNA expression between the diseases caused by CD45RB^high T cells without the regulatory population, and CD45RB^high T cells plus the regulatory population and anti–TGF-β demonstrate that TGF-β is...
Table 1. Protection from Colitis Transferred by CD45RBlowCD4+ T Cells Is Dependent on TGF-β

| Phenotype of CD4+ T cell inoculum | Protocol 1 | Protocol 2 |
|----------------------------------|------------|------------|
|                                  | Number of mice with severe colitis | Weight 6w/0w (%) | Number of mice with severe colitis | Weight 6w/0w (%) |
| $4 \times 10^5$ CD45RBlow        | 3.3 ± 0.3  | 8/10       | $89.7 ± 2$                        | 2.9 ± 0.1  | 9/10       | $89.9 ± 2$                        |
| $4 \times 10^5$ CD45RBlow + 2 × 10^5 CD45RBlow + anti-TGF-β mAb | 2.0 ± 0.4  | 6/11       | $85.7 ± 4$                        | 3.1 ± 0.1  | 7/7       | $87.9 ± 1$                        |
| $4 \times 10^5$ CD45RBlow + 2 × 10^5 CD45RBlow + isotype control mAb | 0.3 ± 0.2  | 0/11       | 110.8 ± 3                        | **0 ± 0  | 0/7       | 104.2 ± 4                        |
| Unreconstituted SCID             | 0 ± 0      | 0/5        | 108.3 ± 3                        | ND        | ND        | ND                                |
|                                  | 7 wk after reconstitution, mice were killed and colon pathology was graded. Data represent the mean colitis score plus SE. |
|                                  | *Severe colitis means grade 3 and above. Weight at 6 wk as a percentage of starting weight. Data represent the mean with SE for the group. |
|                                  | **Statistically significantly different (P <0.05, Wilcoxon rank sum test) to mice restored with $4 \times 10^5$ CD45RBlow + 2 × 10^5 CD45RBlow + isotype control mAb. |
|                                  | *'Mice in this group were not treated with isotype control mAb. |

C.B-17 scid mice were injected intraperitoneally with sorted CD4+ T cell subsets; some mice were treated with anti-TGF-β or isotype control mAb intraperitoneally as indicated. Protocol 1 contains pooled data from two independent experiments in which antibody treated mice were given 2 mg mAb at the time of T cell reconstitution and 1 mg weekly up to 6 wk. Protocol 2 contains data from one experiment in which antibody-treated mice were given 2 mg mAb weekly up to 6 wk.

A key mediator of the regulatory activity of CD45RBlow T cells, rather than a direct inducer of an unrelated colon inflammation.

Differentiation and Effector Function of the Regulatory CD45RBlow Population Is IL-4 Independent. Inhibition of colitis by CD45RBlow CD4+ T cells was not blocked by administration of anti-IL-4 mAbs (5), suggesting that IL-4 production was not necessary for the TGF-β-dependent regulatory mechanism. However, these experiments did not establish whether IL-4 was necessary for the develop-

Figure 1. Treatment with anti-TGF-β mAb abrogates protection from colitis transferred by CD45RBlowCD4+ T cells. Severe colitis in C.B-17 scid mice restored with (A) 4 × 10^5 CD45RBlow-CD4+ cells or (B) 4 × 10^5 CD45RBlow plus 2 × 10^5 CD45RBlow-CD4+ cells, treated weekly with 2 mg anti-TGF-β mAb as described in Table 1. (C) Protection from colitis in mice restored with 4 × 10^5 CD45RBlow-CD4+ plus 2 × 10^5 CD45RBlowCD4+ cells and treated weekly with isotype control mAb. Colon sections were stained with hematoxylin and eosin and photographed. ×90.
ment of the regulatory population of cells themselves. The relationship, if any, between Th2 cells and TGF-β-producing regulatory cells is not yet clear, although several lines of evidence suggest a common origin. T cell clones from orally tolerized mice include many that secrete TGF-β and the Th2 cytokines IL-4 and IL-10 (10), and some human Th2-like clones change to TGF-β-producing cells when stimulated with altered peptide ligands (13). IL-4 is the only known inducer of Th2 differentiation in mice (14, 15), and a requirement for IL-4 in the development of regulatory CD45RB<sup>high</sup> cells would provide additional support for a relationship between the two populations. To address this, CD45RB<sup>low</sup> cells from IL-4-deficient and wild-type (WT) mice were compared for their ability to inhibit colitis induced by WT CD45RB<sup>high</sup> cells. As IL-4-deficient mice were available on the 129 but not the BALB/c background, RAG-2-deficient mice on the 129 background were used as immunodeficient recipients. The great majority of RAG-2-deficient mice restored with CD45RB<sup>high</sup> CD4<sup>+</sup> T cells from syngeneic donors developed colitis very similar to that observed in C.B-17 <sup>sid</sup> mice (Table 2). CD45RB<sup>low</sup>CD4<sup>+</sup> T cells were present in both IL-4-deficient and WT mice (data not shown), and the populations from both mice were equally able to inhibit colitis and wasting disease. The average grade of colitis in the group reconstituted with IL-4-deficient cells was 0.8, and only 1 of 21 mice developed severe colitis (Table 2). In one experiment, neutralizing doses of the anti-IL-4 mAb 11B11 were administered weekly to mice reconstituted with IL-4-deficient cells was 0.8, and only 1 of 21 mice developed severe colitis (Table 2). In one experiment, neutralizing doses of the anti-IL-4 mAb 11B11 were administered weekly to mice reconstituted with IL-4-deficient cells. As IL-4-deficient mice were available on the 129 but not the BALB/c background, RAG-2-deficient mice on the 129 background were used as immunodeficient recipients. The great majority of RAG-2-deficient mice restored with CD45RB<sup>high</sup> CD4<sup>+</sup> T cells from syngeneic donors developed colitis very similar to that observed in C.B-17 <sup>sid</sup> mice (Table 2). CD45RB<sup>low</sup>CD4<sup>+</sup> T cells were present in both IL-4-deficient and WT mice (data not shown), and the populations from both mice were equally able to inhibit colitis and wasting disease. The average grade of colitis in the group reconstituted with IL-4-deficient cells was 0.8, and only 1 of 21 mice developed severe colitis (Table 2). In one experiment, neutralizing doses of the anti-IL-4 mAb 11B11 were administered weekly to mice reconstituted with IL-4-deficient cells. As IL-4-deficient mice were available on the 129 but not the BALB/c background, RAG-2-deficient mice on the 129 background were used as immunodeficient recipients. The great majority of RAG-2-deficient mice restored with CD45RB<sup>high</sup> CD4<sup>+</sup> T cells from syngeneic donors developed colitis very similar to that observed in C.B-17 <sup>sid</sup> mice (Table 2). CD45RB<sup>low</sup>CD4<sup>+</sup> T cells were present in both IL-4-deficient and WT mice (data not shown), and the populations from both mice were equally able to inhibit colitis and wasting disease. The average grade of colitis in the group reconstituted with IL-4-deficient cells was 0.8, and only 1 of 21 mice developed severe colitis (Table 2). In one experiment, neutralizing doses of the anti-IL-4 mAb 11B11 were administered weekly to mice reconstituted with CD45RB<sup>high</sup> cells from WT donors and CD45RB<sup>low</sup> cells from IL-4-deficient mice to block any possible IL-4 production from sources other than the donor CD45RB<sup>low</sup> population. These mice were still significantly protected from severe colitis (data not shown), demonstrating unambiguously that the regulatory population of CD45RB<sup>low</sup> cells is present and mediates its immunoregulatory function in IL-4-deficient mice.

Discussion

The experiments presented here identify a subpopulation of CD4<sup>+</sup> T cells that is present in normal mice and is essential for the prevention of Th1-mediated inflammation in the intestine. Inhibition of colitis by CD45RB<sup>low</sup> cells was completely ablated by an anti-TGF-β mAb, providing direct evidence that TGF-β is an important mediator of the natural immune regulatory mechanism involved in control of intestinal immune responses. Immunoregulatory subpopulations of CD4<sup>+</sup> T cells that have the ability to inhibit the development of spontaneous organ-specific autoimmune diseases, including thyroiditis, gastritis, oophritis, and diabetes, have been identified in normal mice and rats; however, their mechanism of action has not been determined (16–18). It is possible that TGF-β plays a similar role in this active mechanism of peripheral tolerance, as has been established here for the regulation of mucosal immune responses.

The suppression of Th1 responses has been shown, in some instances, to be a property of Th2 cells, in part by production of IL-4 (5, 19, 20). In this model of colitis, however, the protection could not be blocked by an anti-IL-4 mAb (5), and CD45RB<sup>low</sup> cells isolated from IL-4--
deficient mice were able to protect from colitis as well as the same population isolated from WT mice. Taken together, these data indicate that the TGF-β–dependent regulatory population both develops and functions normally in the absence of IL-4. Recently, similar forms of colitis have been shown to develop in TCR-α chain–deficient mice (21), IL-2–deficient mice (22), and IL-10–deficient mice (23), among others, providing support for the idea that intestinal immune responses are regulated normally by a subpopulation of regulatory T cells (24). Whether these other models are deficient in the TGF-β–dependent regulation described here remains to be established.

There is now a large body of data correlating the induction of TGF-β with a subsequent state of antigen-specific systemic hyporesponsiveness induced by oral administration of antigen (25). CD4+ T cell clones (10) and CD8+ populations (9) derived from mice fed myelin basic protein were able to inhibit the induction of active experimental allergic encephalomyelitis, a Th1-mediated autoimmune disease, by a mechanism that involved TGF-β. Many of the regulatory CD4+ T cell clones also secreted IL-4 and IL-10; however, the roles of these cytokines in the regulatory activity of the clones were not tested. The present findings identify TGF-β as a key inhibitor of pathogenic Th1 responses in a very different disease model and show the importance of this mode of regulation in normal mucosal unresponsiveness in vivo.

TGF-β1–deficient mice developed a severe multiple organ inflammatory disease that was lethal by 3–5 wk of age, with the most severe lesions being present in the heart and lungs (26, 27). The cellular infiltration in affected organs was associated with increases in the inflammatory cytokines IFN-γ and TNF-α (26), suggesting that TGF-β1 is important for the prevention of dysregulated inflammatory responses in many organs. Interestingly, inflammation in the intestine of the TGF-β1–deficient mice was usually mild, although gastric inflammation was severe on some genetic backgrounds. These observations appear to be at odds with the findings from the scid transfer experiments, in which an absence of CD45RBlow, TGF-β–dependent regulatory cells led to the development of severe inflammation restricted primarily to the colon. Mild inflammation was seen in the lung and stomach of some scid mice restored with CD45RBhighCD4+ T cells (3). This difference may be related to (a) a strain dependency in the susceptibility of mice to develop colitis, or (b) the presence of TGF-β2 and TGF-β3 in TGF-β1–deficient mice, isoforms that would be inhibited in reconstituted scid mice treated with the mAb that neutralizes all three isoforms of TGF-β. TGF-β1, 2, and 3 have all been shown to be present in murine small and large intestine (28), and it may be that TGF-β2 and TGF-β3 play a protective role in the intestine of TGF-β1–deficient mice.

In summary, the finding that suppression of colitis by CD45RBlow cells was dependent on TGF-β but independent of IL-4 has provided valuable information on the mechanism of action of these natural regulatory cells. A thorough understanding of the development, effector function, and antigen specificity of these cells will provide a backbone of information with which to devise immune interventions favoring the development of TGF-β–dependent regulatory cells rather than pathogenic Th1 responses. Such immune therapy may be useful for treatment of a number of autoimmune diseases, including IBD.

We gratefully acknowledge the expert technical assistance of the staff of the Histology Laboratory at the Schering-Plough Research Institute and J. Polakoff, E. Callas, and Dr. J. Cupp for FACS® sorting. The original breeding stock for the 129 IL4T mice was generously provided by Drs. Werner Müller, Ralph Kühn, and Klaus Rajewsky.

DNAX Research Institute of Molecular and Cellular Biology Inc. is supported by the Schering-Plough Corporation.

Address correspondence to F. Powrie or R.L. Coffman, DNAX Research Institute of Molecular and Cellular Biology, 901 California Avenue, Palo Alto, CA 94304.

Received for publication 2 January 1996 and in revised form 8 March 1996.

References
1. Sartor, R.B. 1991. Pathogenetic and clinical relevance of cytokines in inflammatory bowel disease. Immunol. Res. 10: 465–471.
2. Morrissey, P.J., K. Charrier, S. Braddy, D. Liggitt, and J.D. Watson. 1993. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J. Exp. Med. 178:237–244.
3. Powrie, F., M.W. Leach, S. Mauze, L.B. Caddle, and R.L. Coffman. 1993. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C.B-17 scid mice. Int. Immunol. 5:1461–1471.
4. Powrie, F., M.W. Leach, S. Mauze, S. Menon, L.B. Caddle, and R.L. Coffman. 1994. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted
with CD45RB\(^{hi}\) CD4\(^{+}\) T cells. *Immunity.* 1:553–562.
5. Powrie, F., R. Correa-Oliveira, S. Maue, and R.L. Coffman. 1994. Regulatory interactions between CD45RB\(^{hi}\) and CD45RB\(^{lo}\) CD4\(^{+}\) T cells are important for the balance between protective and pathogenic cell-mediated immunity. *J. Exp. Med.* 179:589–600.
6. Moore, K.W., A. O’Garra, R. de Waal Malefyt, P. Vieira, and T.R. Mosmann. 1993. Interleukin-10. *Annu. Rev. Immunol.* 11:165–190.
7. Powrie, F. and R.L. Coffman. 1993. Cytokine regulation of T-cell function: potential for therapeutic intervention. *Immunol. Today.* 14:270–274.
8. Sher, A., R.T. Gazzinelli, I.P. Oswald, M. Clerici, M. Kullberg, E.J. Pearce, J.A. Berzofsky, T.R. Mosmann, S.L. James, H.C. Morse, and G.M. Shearer. 1993. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. *Immunol. Rev.* 127:183–204.
9. Miller, A., O. Lider, A.B. Roberts, M.B. Sporn, and H.L. Weiner. 1992.Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. *Proc. Natl. Acad. Sci. USA.* 8:421–425.
10. Chen, Y., V.K. Kuchroo, J. Inobe, D.A. Hafler, and H.L. Weiner. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. *Science (Wash. DC).* 265:1237–1240.
11. Coffman, R.L. 1982. Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development. *Immunol. Rev.* 69:5–23.
12. Dasch, J.R., D.R. Pace, W. Waegell, D. Inenaga, and L. Ellingsworth. 1989. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor-beta2 affinity purification. *J. Immunol.* 142:1536–1541.
13. Windhagen, A., C. Scholz, P. Holhsberg, H. Fukaura, A. Sette, and D.A. Hafler. 1995. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. *Immunity.* 2:373–380.
14. Coffman, R.L., K. Varkila, P. Scott, and R. Chatelain. 1991. The role of cytokines in the differentiation of CD4\(^{+}\) T cell subsets in vivo. *Immunol. Rev.* 123:189–207.
15. Seder, R.A., and W.E. Paul. 1994. Acquisition of lymphokine-producing phenotype by CD4\(^{+}\) T cells. *Annu. Rev. Immunol.* 12:635–673.
16. Sakaguchi, S., K. Fukuma, K. Kuribayashi, and T. Masuda. 1985. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. *J. Exp. Med.* 161:72–87.
17. Powrie, F., and D. Mason. 1990.OX-22\(^{hi}\) CD4\(^{+}\) T cells induce wasting disease with multiple organ pathology; prevention by the OX-22low subset. *J. Exp. Med.* 172:1701–1708.
18. Fowell, D., and D. Mason. 1993. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4\(^{+}\) T cell subset that inhibits this autoimmune potential. *J. Exp. Med.* 177:627–636.
19. Kuchroo, V.K., M.P. Das, J.A. Brown, A.M. Ranger, S.S. Zamel, R.A. Sobel, H.L. Weiner, N. Nabavi, and L.H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. *Cell.* 80:707–718.
20. Saoudi, A., S. Simmonds, I. Huitinga, and D. Mason. 1995. Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells. *J. Exp. Med.* 182:335–344.
21. Mombaerts, P., E. Mizoguchi, M.J. Gruss, L.H. Glimcher, A.K. Bhan, and S. Tonegawa. 1992. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. *Cell.* 75:274–282.
22. Sadlack, B., H. Merz, H. Schorle, A. Schimpl, A.C. Feller, and I. Horak. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. *Cell.* 75:253–261.
23. Kuhn, R., J. Kohler, D. Renneck, K. Rajewsky, and W. Muller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell.* 75:263–274.
24. Powrie, F. 1995. T cells in inflammatory bowel disease: protective and pathogenic roles. *Immunity.* 3:171–174.
25. Weiner, H.L., A. Friedman, A. Miller, S.J. Khoury, A. al-Sabbagh, L. Santos, M. Sayegh, R.B. Nussenblatt, D.E. Trentham, and D.A. Hafler. 1994. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. *Annu. Rev. Immunol.* 12:809–837.
26. Shull, M.M., I. Ormsby, A.B. Kier, S. Pavlovski, R.J. Diedbold, M. Yin, R. Allen, C. Sidman, G. Proetzcl, D. Calvin, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta1 gene results in multifocal inflammatory disease. *Nature (Lond.).* 359:693–699.
27. Kulkami, A.B., C.G. Huh, D. Becker, A. Geiser, M. Lyght, K.C. Flanders, A.B. Roberts, M.B. Sporn, J.M. Ward, and S. Karlsson. 1993. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. *Proc. Natl. Acad. Sci. USA.* 90:770–774.
28. Barnard, J.A., G.J. Warwick, and L.I. Gold. 1993. Localization of transforming growth factor beta isoforms in the normal murine small intestine and colon. *Gastroenterology.* 105:67–73.